Study of experimental drug IDOV-SAFE for advanced digestive cancers
Part of Cancer, Digestive system clinical trials.
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have an advanced digestive system cancer (such as MSS colorectal, bile duct, stomach, esophageal, or liver cancer) that has gotten worse during or after standard treatments, or you cannot tolerate standard chemotherapy.
- You must be in fairly good physical condition (able to do light activities) and have an expected survival of at least 3 months.
- You must have at least one tumor that can be measured on scans, and it has not been treated with radiation recently or has grown after radiation.
- You must have adequate organ function (bone marrow, liver, kidneys) as determined by blood tests.
- You cannot have severe infections, active autoimmune diseases, recent major heart or blood vessel problems, or have had certain vaccines like smallpox or monkeypox in the last 10 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new intravenous drug called IDOV-SAFE in people with advanced solid tumors that have stopped responding to standard treatments or have no effective standard option. The goal is to see if it is safe and effective.
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug called IDOV-SAFE given through a vein. It is for people with advanced solid tumors that have not responded to standard treatments. The study aims to see if the drug is safe and if it can help shrink tumors.
Hear when a new Advanced Malignant Solid Tumor of Digestive System trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.